Dose-intense treatment of mantle cell lymphoma: Can durable remission be achieved?

Current Opinion in Oncology

Volumn 20, Issue 5, 2008, Pages 487-494

  Dreyling, Martin ^a,b   Hiddemann, Wolfgang ^a,b  

^a European MCL Network   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Autologous transplantation; HyperCVAD; Mantle cell lymphoma; Rituximab

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; BORTEZOMIB; BUSULFAN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLAVOPIRIDOL; FLUDARABINE; IBRITUMOMAB TIUXETAN; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; VINCRISTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; CVAD PROTOCOL; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATALITY; GRAFT VERSUS HOST REACTION; GROUPS BY AGE; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUROPATHY; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; REMISSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; PREDNISONE; REMISSION INDUCTION; VINCRISTINE;

EID: 59649119515     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32830b61c2     Document Type: Review

References (50)

1. Jaffe ES, Harris NL, Stein H. Tumours of the haemopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
2. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106:4315-4321.
3. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7:750-762. An excellent overview of molecular pathogenesis of MCL.
4. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3:185-197.
5. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131:29-38.
6. Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of the clinical risk in mantle cell lymphoma. Blood 2006; 107:3407.
7. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced stage mantle cell lymphoma patients treated with anti-CD20 immunochemo-therapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111:2385-2387.
8. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2008; 111:558-565. Establishment of a combined clinical and biological risk score in MCL based on almost 500 patients uniformly treated within prospective trials.
9. Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006; 107:2271-2278.
10. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20:1288-1294.
11. Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Current management of mantle cell lymphoma. Drugs 2007; 67:1689-1702. An up-to-date overview of current treatment options in MCL.
12. Herald M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006; 132:105-112.
13. Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998; 16:1922-1930.
14. Nickenig C, Dreyling M, Hoster E, et al., for the German Low Grade Lymphoma Study Group (GLSG). CHOP improves response rates but not survival and has a lower hematologie toxicity as compared to MCP in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Cancer 2006; 107:1014-1022.
15. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23:1984-1992.
16. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105:2677-2684.
17. Rummel MJ, von Grünhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphoma: first interim results of a randomized phase III study of the StiL (Study Group indolent Lymphomas, Germany) [abstract #385]. Blood 2007; 110.
18. Dreger P, Rieger M, Seyfarth B, et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 2007; 92:42-49.
19. Lefrere F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16:587-593.
20. Lefrere F, Delmer A, Levy V, et al. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004; 89:1275-1276.
21. de Guibert S, Jaccard A, Bernard M, et al. Rituximab and DHAP followed by intensive therapy with autologous stem cell transplantation as first line therapy for mantle cell lymphoma. Haematologica 2006; 91:425-426.
22. Dreyling M, Hoster E, Hermine O, et al. European MCL Network: an update on current first line trials [#388]. Blood 2007; 110.
23. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high dose metho-trexate and cytarabine. J Clin Oncol 2005; 23:7013-7023.
24. Epner EM, linger J, Miller T, et al. A multi center trial of hyperCVAD+Rituxan in patients with newly diagnosed cell lymphoma [abstract #387]. Blood 2007; 110.
25. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle cell lymphoma. J Clin Oncol 1998; 16:3803-3809.
26. Ritchie DS, Seymour JF, Grigg AP, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007; 86:101-105.
27. Till BG, Gooley TA, Crawford N, et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008; 29:1-12.
28. Vose J, Loberiza F, Bierman P, et al. Mantle cell lymphoma (MCL): induction therapy with HyperCVAD/high dose methotrexate and cytarabine (M-C) (+/-rituximab) improves results of autologous stem cell transplant in first remission [abstract #7511]. J Clin Oncol 2006; 18S.
29. Geisler CH, Elonen E, Kolstad A, et al. Mantle cell lymphoma can be cured by intensive immunochemotherapy with in vivo purged stem cell support: final report of the Nordic Lymphoma Group MCL2 Study. Blood (ASH Annual Meeting Abstracts) 2007; 110:LB1.
30. Herald M, Pasold R, Srock S, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL). Blood 2004; 104 (Suppl 1):584a.
31. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:3064-3071.
32. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383-3389.
33. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99:706-714. A Cochrane meta-analysis with the provocative results of similar improvement of overall survival after combined immunochemotherapy in follicular as well as MCL.
34. Younes A, Pro B, Rodriguez MA, et al. Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract #2452]. Blood 2005; 106:689a.
35. Weigert O, Jurczak W, Schilling C, et al. Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL Network and the PLRG. Proc Am Soc Clin Oncol 2006; 24 (18S):430s.
36. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radio-immunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99:3158-3162.
37. Smith MR, Zhang L, Gordon LI et al. Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group study E1499 [abstract #389]. Blood 2007; 110. Although a preliminary study, the results of this phase II study suggest a significant improved progression-free survival after RIT consolidation.
38. Dreyling M, Bergsagel PL, Gordon LI, Cotter FE. Mantle cell lymphoma and other t(11;14) disorders: how biology can drive therapy. ASCO Educational book 2006, 476-484.
39. Martin P, Chadburn A, Christos P, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding seven years with standard therapies. Ann Oncol 2008 [Epub ahead of print]. Provocative results of a retrospective survey of patients treated only with conventional chemotherapy. The excellent results emphasize the role of patient selection in monocenter trials.
40. Ganti AK, Bierman PJ, Lynch JC, et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005; 16:618-624.
41. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21:4407-4412.
42. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104:3535-3542.
43. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104:3865-3871.
44. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100:4310-4316.
45. Fisher Rl, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24:4867-4874.
46. Weigert O, Pastore A, Rieken M, et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007; 21:524-528.
47. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104:2269-2271.
48. Wiernik PH, Lossos I, Tuscano J, et al. Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma [abstract #531]. Blood 2006; 108 (Suppl 11):69.
49. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsir-olimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23:5347-5356.
50. Hess G, Romaguera J, Verhoef G, et al. Phase 3 study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy. Proc Am Soc Clin Oncol 2008; 26 (18S):457s.